HGF and neoplasm: We have also used MAME as a preclinical model to test the effects of cabozantinib on the tumor-promoting interactions between different triple-negative breast cancer cells, representing various molecular subtypes of the disease, and CAFs and normal fibroblasts overexpressing HGF [78].